BioTuesdays

Tag - Chardan

DURECT
Markets

Chardan starts DURECT at buy; PT $7

Chardan Capital Markets launched coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and price target of $7. The stock closed at $1.76 on Oct. 29. “We expect that DURECT’s lead pipeline asset, DUR-928, will...

October 30, 2020
Axcella Logo
Markets

Chardan starts Axcella Health at buy; PT $16

Chardan Capital Markets initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $16 price target. The stock closed at $4.45 on Oct. 26 “We expect that Axcella’s pipeline of endogenous metabolic...

October 27, 2020
Feature

Chardan president, Jonas Grossman, talks SPACs

By Abby Hardy As president of Chardan, an independent, global investment bank specializing in healthcare, disruptive technologies, and special purpose acquisition companies (SPACs), Jonas Grossman takes a worldwide view...

June 25, 2019